anti-Casein Kinase 2, alpha 1 Polypeptide (CSNK2A1) Antikörper

Human Casein Kinase 2, alpha 1 Polypeptide (CSNK2A1) Interaktionspartner

1. Results show that casein kinase 2 alpha (CK2 )downregulation leads to H3K9me3 and senescence-associated heterochromatic foci (SAHF) formation by increasing H3K9 trimethylase SUV39h1 (SUV39h1) and decreasing H3K9 dimethylase G9a (G9a).

2. Rad17-S667 in the C-terminal tail is constitutively phosphorylated in vivo in a casein kinase 2-dependent manner, and the phosphorylation is important for 9-1-1 interaction

3. This and previous studies have found a total of 20 CSNK2A1 variants in 28 individuals with syndromic intellectual disability. The hotspot variant c.593A>G, p.(Lys198Arg) was found in eight of 28 patients. Meanwhile, only five CSNK2B variants were identified in five individuals with neurodevelopmental disorders. We reviewed the previous literature to verify the phenotypic spectrum of CSNK2A1- and CSNK2B-related syndromes

4. Mutation in CSNK2A1 cause neurodevelopmental abnormalities and dysmorphic features.

5. Our findings indicate that CD163 contributes to gliomagenesis via CK2 and provides preclinical evidence that CD163 and the CD163 pathway might serve as a therapeutic target for glioma.

6. Multiple conformations of kinase II subunit alpha (CK2alpha) hinge region, located near the active site, were observed during the dynamics.

7. New crystal forms were exploited and one provided a crystal structure of CK2alpha2 at 1.89A resolution.

8. Casein kinase II, glycogen synthase kinase-3, and Ikaros mediated regulation of leukemia has been summarized. (Review)

9. Our results showcase the potentially valuable functional impact of microRNAs in regulating GG related epilepsy. As CK-2alpha inhibition enhances miR-217 expression, disrupting the miR-217-CK-2alpha interplay through CK-2alpha inhibitors might represent a novel therapeutic strategies aimed at LEAT.

10. The results suggest that CK2alpha promotes migration and invasion of clear cell renal cell carcinoma and therefore could serve as a novel prognostic biomarker and molecular therapeutic target in this type of cancer.

11. The newly designed casein kinase 2 (CK2) Inhibitors were screened on one lung cancer cell line A549, showing low micromolar anti-proliferative activity.

12. CK2 governs the molecular decision between encephalitogenic TH17 cells and protective Treg cells development.

13. Data suggest that casein kinase 2 (CK2) inhibition is a promising approach to blocking beta-catenin in MPNST cells, although combinatorial therapies may be required for maximal efficacy.

14. Results provide evidence that CK2A is critical fro RSV virus replication in human cells.

15. Vascular smooth muscle protein kinase CK2 inhibition suppresses neointima formation via a proline-rich homeodomain-dependent mechanism.

16. we have identified kinases, particularly CK2, associated with the autocrine malignant cell network that may play a central role in sustaining the cytokine network and/or mediating its effects in ovarian cancer.

17. CK2 and AKT display a high degree of cross-regulation of their respective functions, both directly, through physical interaction and phosphorylation, and indirectly, through an intense cross-talk of key downstream effectors, ultimately leading to sustained AKT activation. (Review)

18. Phosphorylation of Ikaros by CK2 impairs Ikaros DNA-binding ability, as well as Ikaros ability to regulate gene expression and function as a tumor suppressor in leukemia. (Review)

19. data implicate CK2 as a regulator of the Th17/Treg axis and Th17 cell maturation and suggest that CK2 could be targeted for the treatment of Th17 cell-driven autoimmune disorders.

20. This study demonstrates that CSNK2A1 and SIRT6 are indicators of poor prognosis for breast carcinomas and that CSNK2A1-mediated phosphorylation of SIRT6 might be involved in the progression of breast carcinoma.

Silk Worm Casein Kinase 2, alpha 1 Polypeptide (CSNK2A1) Interaktionspartner

1. To clarify the control mechanism of the catalytic activity of casein kinase 2 (CK2) during early embryonic development in the silkworm, Bombyx mori, attempted an in-vitro functional analysis by using the recombinant alpha and beta subunits of B. mori CK2

Maize/Corn (Zea mays) Casein Kinase 2, alpha 1 Polypeptide (CSNK2A1) Interaktionspartner

1. identify the the ZmeIF5A serine residues phosphorylated by CK2

2. analysis of free energy differences of binding of adenosine triphosphate (ATP) and guanine triphosphate (GTP) to the protein kinase CK2

3. The complex structure between a C-terminal deletion mutant of human CK2alpha and the ATP-competitive inhibitor emodin is studies in comparison with with a previously published complex structure of emodin and maize CK2alpha.

4. The regulatory subunit of protein kinase CK2 is identified as a novel intracellular partner of AdipoR1 and CK2 is shown to be an effector molecule in adiponectin signaling.

5. CK2alpha-4 is a splicing variant of maize protein kinase CK2, and may function as a negative regulator of other CK2s.

Mouse (Murine) Casein Kinase 2, alpha 1 Polypeptide (CSNK2A1) Interaktionspartner

1. these data suggest that Fcgamma receptor/reactive oxygen species/CK2alpha is a key inducer of NF-kappaB activation in airway epithelial cells in a murine model of asthma

2. Data (including data from studies using knockout mice) suggest that Brg1 is phosphorylated by casein kinase 2 (Ck2; Ck2alpha1 and Ck2alpha-prime are catalytic subunits) in proliferating skeletal myoblasts; Brg1 is catalytic subunit of SWI/SNF chromatin-remodeling enzymes; Ck2-mediated phosphorylation of Brg1 appears to regulate myoblast proliferation. (Brg1 = Brahma-related gene 1 protein)

3. Casein kinase 2 plays a central role in striatal physiology and in severity of l-DOPA-induced dyskinesia.

4. Casein kinase 1 (alpha, delta and epsilon) localize at the spindle poles, but may not be essential for mammalian oocyte meiotic progression.

5. These data support a model in which activated Akt enhances rRNA synthesis both by preventing TIF-IA degradation and phosphorylating CK2alpha, which in turn phosphorylates TIF-IA.

6. An essential role of CK2alpha in the mammalian circadian clock.

7. receptor beta and its domains interact with casein kinase 2, phosphokinase C, and N-myristoylation sites of mitochondrial and nuclear proteins in mouse brain

8. CK2alpha levels are predominant in comparison to CK2alpha' levels throughout the mammalian brain.

9. The overall phenotype found in CK2alpha (-/- ) mice, is described.

10. These experiments demonstrate that combined loss of one CK2alpha allele and both CK2alpha' alleles leads to unique abnormalities of growth and development.

11. TNP1 is a newly identified binding partner of the alpha-subunit of casein kinase 2.

12. Casein kinase II has a role in phosphorylation of NF-kappaB p65 subunit enhancement of inducible nitric-oxide synthase gene transcription

13. CK2 selectively phosphorylates MKP3, suggesting cross-regulation between CK2alpha and MKP3, as well as a modulation of ERK2-MAPK signaling by CK2alpha via MKP3

14. In cultured hippocampal neurons, the capacity of Nerve Growth Factor to promote axon elongation is mostly mediated by p75NTR, and the activation of this pathway leads to the inactivation of GSK-3beta.

15. CK2 involvement in the phenomenon of the drug resistance was investigated.

16. CK2alpha has an essential role in embryogenesis, as mice lacking CK2alpha die in mid-embryogenesis, with cardiac and neural tube defects.

17. These results suggest that Ikaros acts as a negative regulator on iNOS expression.

18. The balance between beta-arr and CK1/2 determines whether WNT/RAC-1 or other non-canonical WNT pathways are activated.

19. reversible phosphorylation of CK2alpha requires precise regulation to allow proper mitotic progression

20. CAPS activity in priming vesicle exocytosis requires CK2 phosphorylation

Cow (Bovine) Casein Kinase 2, alpha 1 Polypeptide (CSNK2A1) Interaktionspartner

1. Involvement of ubiquitous protein kinase CK2 in angiogenesis. Naturally derived CK2 inhibitors may be useful for treatment of proliferative retinopathies. (Protein kinase CK2)